Table 1.
Total (N=18) | |
---|---|
Dose Level (twice daily) | |
200 mg | 3 (16.7%) |
250 mg | 3 (16.7%) |
300 mg | 5 (27.8%) |
350 mg | 7 (38.9%) |
Age (years) | |
N | 18 |
Mean (SD) | 59.1 (11.9) |
Median | 62.5 |
Q1, Q3 | 58.0, 67.0 |
Range | (24.0–75.0) |
Race | |
White | 15 (83.3%) |
Black or African American | 1 (5.6%) |
American Indian or Alaska Native | 1 (5.6%) |
Unknown: Patient unsure | 1 (5.6%) |
Gender | |
Female | 9 (50.0%) |
Male | 9 (50.0%) |
ECOG Performance Status | |
0 | 10 (55.6%) |
1 | 8 (44.4%) |
Primary Tumor Site | |
Hypopharynx | 5 (27.8%) |
Larynx | 5 (27.8%) |
Lip and oral cavity | 4 (22.2%) |
Nasal cavity and ethmoid sinus | 1 (5.6%) |
Oropharynx | 3 (16.7%) |